Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?
Michel R. Langlois, Allan D. Sniderman
Current Cardiology Reports (2020) Vol. 22, Iss. 8
Closed Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
Henry N. Ginsberg, Chris J. Packard, M. John Chapman, et al.
European Heart Journal (2021) Vol. 42, Iss. 47, pp. 4791-4806
Open Access | Times Cited: 529
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Jennifer Behbodikhah, Saba Ahmed, Ailin Elyasi, et al.
Metabolites (2021) Vol. 11, Iss. 10, pp. 690-690
Open Access | Times Cited: 181
Ten things to know about ten cardiovascular disease risk factors
Harold Bays, Pam R. Taub, Elizabeth Epstein, et al.
American Journal of Preventive Cardiology (2021) Vol. 5, pp. 100149-100149
Open Access | Times Cited: 170
Ten things to know about ten cardiovascular disease risk factors – 2022
Harold Bays, Anandita Agarwala, Charles German, et al.
American Journal of Preventive Cardiology (2022) Vol. 10, pp. 100342-100342
Open Access | Times Cited: 79
Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook
Vikrama Raja, Carlos Aguíar, Nasreen Al-Sayed, et al.
Atherosclerosis (2023) Vol. 383, pp. 117312-117312
Open Access | Times Cited: 62
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Emil Hagström, Philippe Gabríel Steg, Michael Szarek, et al.
Circulation (2022) Vol. 146, Iss. 9, pp. 657-672
Open Access | Times Cited: 66
ApoB100 and Atherosclerosis: What’s New in the 21st Century?
Dimitris Kounatidis, Natalia G. Vallianou, Aikaterini Poulaki, et al.
Metabolites (2024) Vol. 14, Iss. 2, pp. 123-123
Open Access | Times Cited: 15
Trends in epidemiology of dyslipidemias in India
Sonali Sharma, Kiran Gaur, Rajeev Gupta
Indian Heart Journal (2024) Vol. 76, pp. S20-S28
Open Access | Times Cited: 11
Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape—focus on hypertriglyceridaemia
Bilal Bashir, Jonathan Schofield, Paul Downie, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 8
Clinical significance of small dense low‐density lipoprotein cholesterol measurement in type 2 diabetes
Tsutomu Hirano
Journal of Diabetes Investigation (2025)
Open Access | Times Cited: 1
Discordance Analyses Comparing LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B for Cardiovascular Risk Estimation
Camilla Ditlev Lindhardt Johannesen, Martin Bødtker Mortensen, Børge G. Nordestgaard, et al.
Atherosclerosis (2025) Vol. 403, pp. 119139-119139
Closed Access | Times Cited: 1
Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
Chris J. Packard
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 3, pp. 133-142
Open Access | Times Cited: 33
Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice
Diana De Oliveira-Gomes, Parag H. Joshi, Eric D. Peterson, et al.
Circulation (2024) Vol. 150, Iss. 1, pp. 62-79
Closed Access | Times Cited: 6
Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations
Dieter Lütjohann, Hans‐Ulrich Klör, Frans Stellaard
Nutrients (2023) Vol. 15, Iss. 9, pp. 2202-2202
Open Access | Times Cited: 15
Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment
Federica Galimberti, Manuela Casula, Elena Olmastroni
Pharmacological Research (2023) Vol. 195, pp. 106873-106873
Open Access | Times Cited: 15
Use of Apolipoprotein B in the Era of Precision Medicine: Time for a Paradigm Change?
Justine Cole, Rafael Zubirán, Anna Wolska, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 17, pp. 5737-5737
Open Access | Times Cited: 14
Association of remnant cholesterol and non-high density lipoprotein cholesterol with risk of cardiovascular mortality among US general population
Iokfai Cheang, Xu Zhu, Xinyi Lu, et al.
Heliyon (2022) Vol. 8, Iss. 8, pp. e10050-e10050
Open Access | Times Cited: 19
Aneurysm wall enhancement, atherosclerotic proteins, and aneurysm size may be related in unruptured intracranial fusiform aneurysms
Fei Peng, Hao Niu, Xin Feng, et al.
European Radiology (2023) Vol. 33, Iss. 7, pp. 4918-4926
Closed Access | Times Cited: 11
European guidelines for the treatment of dyslipidaemias: New concepts and future challenges
Angela Pirillo, Manuela Casula, Alberico L. Catapano
Pharmacological Research (2023) Vol. 196, pp. 106936-106936
Open Access | Times Cited: 11
Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling
Esther Reijnders, Arnoud van der Laarse, L. Renee Ruhaak, et al.
Clinical Proteomics (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 4
Can we trust published evidence on point-of-care tests for cholesterol? A rapid review
Chikomborero Cynthia Mutepfa, Timothy Hicks, Amanda Winter, et al.
BMJ Open (2025) Vol. 15, Iss. 3, pp. e080726-e080726
Open Access
Safety and efficacy of antisense oligonucleotides on triglyceride, apolipoprotein C-III, and other lipid parameters levels in hypertriglyceridemia; a network meta-analysis of randomized controlled trials
Abdelrahman Mahmoud, Kerollos Abdelsayed, Ahmed Mohamed, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access
Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis
Yue Zhang, Yanrong Suo, Lin Yang, et al.
Cardiology Research and Practice (2022) Vol. 2022, pp. 1-13
Open Access | Times Cited: 18
Discordance of apolipoprotein B with low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol and coronary atherosclerosis
Xin Su, Xueli Cai, Yuesong Pan, et al.
European Journal of Preventive Cardiology (2022) Vol. 29, Iss. 18, pp. 2349-2358
Closed Access | Times Cited: 17
High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine
Esther Reijnders, Arnoud van der Laarse, J. Wouter Jukema, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top